Jinny Park
Hematology Jinny Park Favorite Doctor
  • SpecialtyHematopoietic stem cell transplantation, blood cancers (leukemia, lymphoma, myeloma and blood diseases)
  • Site
Appointment
Schedule
의료진 진료일정
Week M T W T F S
AM     Absent Present    
PM       Present    
Clinical Interests

Hematopoietic stem cell transplantation
Acute/Chronic leukemia
Lumphoma
Myelodysplastic syndrome
Myeloproliferative disorder
Benign blood diseases (anemia, thrombocytopenia, aplastic anemia, blood clotting disorder)

Education
Education
Career
Career
Asan Medical Center, Intern & Resident
Asan Medical Center, Clinical Instructor
Samsung Medical Center, Clinical Instructor
Jeju National University College of Medicine, Assistant Professor
Gachon University College of Medicine, Associate Professor
Gachon University College of Medicine, Professor
<Awards>
AACR-NCI-EORTC travel award (KCSG)
Merit Award 7th Korean Society of Hematopoietic
Stem Cell Transplantation Conference
Merit Award 8th Korean Society of Hematopoietic
Stem Cell Transplantation Conference
More
Community
Community
More
Training
Training
2010 City of Hope National Medical Center, Professor of Exchange (Hematopoietic stem cell transplantation, leukemia, lymphoma, etc.)
License
License
Medical License
Internal Medicine Specialist
Hematology Oncology Specialist
Jinny Park
Paper
Paper
2016 Seo JY, Hong J, Chun K, Jeong J, Cho H, Kim KH, Park J, Ahn JY, Park PW, Lee JH. Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Leuk Lymphoma. 9:1-9, 2016
2016 Byun JM, Kim YJ, Yoon HJ, Kim SY, Kim HJ, Yoon J, Min YH, Cheong JW, Park J, Lee JH, Hong DS, Park SK, Kim HJ, Ahn JS, Shin HJ, Chung JS, Lee WS, Lee SM, Park Y, Kim BS, Lee JH, Lee KH, Jung CW, Jang JH, Min WS, Park TS; AML/MDS working party of Korean Society of Hematology. Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study. Ann Hematol.95(8):1223-32,2016
2016 Hong J, Lee S, Chun G, Jung JY, Park J, Ahn JY, Cho EK, Shin DB, Lee JH. Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma. Blood Res. 51(2):113-21,2016
2016 Jeong JH, Lee HT, Seo JY, Seo YH, Kim KH, Kim MJ, Lee JH, Park J, Hong JS, Park PW, Ahn JY. Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis. Ann Lab Med. 36(4):291-299,2016
2016 Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med. 20. doi: 10.3904,2016
2016 Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Prognostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with Gemcitabine-Based Chemotherapy. Cancer Res Treat. 23. doi: 10.4143,2016
2016 Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, Kim HJ, Kim SH, Zang DY, Oh S, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. Feb 17. pii: haematol.2015.139899, 2016
2016 Park YH, Yi HG, Kim CS, Hong J, Park J, Lee JH, Kim HY, Kim HJ, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY; Gyeonggi/Incheon Branch, The Korean Society of Hematology. Clinical Outcome and Predictive Factors in the Response to Splenectomy in Elderly Patients with Primary Immune Thrombocytopenia: A Multicenter Retrospective Study. Acta Haematol. 135(3):162-71, 2016
2016 Hong J, Woo HS, Ahn HK, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia. Support Care Cancer. 24(1):187-94, 2016
2016 Kim YS, Cho EK, Woo HS, Hong J, Ahn HK, Park I, Sym SJ, Kyung SY, Kang SM, Park JW, Jeong SH, Park J, Lee JH, Shin DB. Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. Cancer Res Treat. 48(1):80-7, 2016
2015 Choi CW, Bang SM, Jang S, Jung CW, Kim HJ, Kim HY, Kim SJ, Kim YK, Park J, Won JH. Guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med. 30(6):771-88, 2015
2015 Park S, Hong J, Hwang I, Ahn JY, Cho EY, Park J, Cho EK, Shin DB, Lee JH. Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy. J Geriatr Oncol. 6(6):470-8, 2015
2015 Kim YS, Sym SJ, Baek MY, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB. Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study. Cancer Chemother Pharmacol. 76(6):1267-72, 2015
2015 Lee HG, Kim SY, Kim I, Kim YK, Kim JA, Kim YS, Lee HS, Park J, Kim SJ, Shim H, Eom HS, Park BB, Lee J, Park SK, Cheong JW, Park KW. Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. Blood Res. 50(3):160-6, 2015
2015 Oh SY, Kim WS, Kim JS, Chae YS, Lee GW, Eom HS, Ryoo HM, Lee S, Kim SJ, Yoon DH, Won JH, Hong J, Park J, Lee SM, Hong JY, Park E, Kim HJ, Yang DH, Kim HJ, Suh C. A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leuk Lymphoma. 2015 Nov 16:1-7. [Epub ahead of print]
2015 Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 6;126(6):746-56, 2015
2015 Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, Kim YK, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW. Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leuk Lymphoma. 2015 Jun 12:1-7. [Epub ahead of print]
2014 Hong J, Woo HS, Kim H, Ahn HK, Sym SJ, Park J, Ahn JY, Cho EK, Shin DB, Lee JH. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci. 105(12):1569-75, 2014
2014 Kim J, Hong J, Kim SG, Hwang KH, Kim M, Ahn HK, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Prognostic Value of Metabolic Tumor Volume Estimated by (18)&#8201;F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease. Nucl Med Mol Imaging.48(3):187-95, 2014
2014 Woo HS, Ahn HK, Lee HY, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Invest New Drugs. 32(6):1311-5, 2014
2014 Park J. Can we more efficiently save patients with vitamin K-dependent coagulopathy caused by superwarfarin intoxication? Korean J Intern Med. 29(4):430-3, 2014
2014 Lee HG, Choi Y, Kim SY, Kim I, Kim YK, Kim YS, Lee HS, Kim SJ, Kim JA, Park BB, Park J, Shim H, Eom HS, Lee J, Park SK, Cheong JW, Park KW. R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. Blood Res. 49(2):107-14, 2014
2014 Yi HG, Lee MH, Kim CS, Hong J, Park J, Lee JH, Han BR, Kim HY, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY; Gyeonggi/Incheon Branch, The Korean Society of Hematology. Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis. Blood Res. 49(2):95-9, 2014
2014 Kim SJ, Cheong JW, Kim DY, Lee JH, Lee KH, Kim YK, Kim HJ, Song IC, Jo DY, Lee JO, Bang SM, Park J, Lee JH, Lee WS, Joo YD, Maeng CH, Yoon HJ, Lee NR, Kwak JY, Kim KH, Won JH, Han BR, Zang DY, Moon JH, Sohn SK, Bae SH, Ryoo HM, Kim SY, Lee MH, Min YH; Korean Society of Hematology AML/MDS Working Party. Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients. Int J Hematol. 100(2):141-51, 2014
2014 Park MJ, Park PW, Seo YH, Kim KH, Seo JY, Jeong JH, Kim MJ, Jeong JW, Ahn JY, Park J. A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib. Ann Lab Med. 34(3):247-51, 2014
2014 Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, Hong J, Sym SJ, Park J, Shin DB, Lee JH, Cho EK. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. Tumour Biol. 35(6):5735-40, 2014
2014 SJ, Cheong JW, Min YH, Choi YJ, Lee DG, Lee JH, Yang DH, Lee SM, Kim SH, Kim YS, Kwak JY, Park J, Kim JY, Kim HG, Kim BS, Ryoo HM, Jang JH, Kim MK, Kang HJ, Cho IS, Mun YC, Jo DY, Kim HY, Park BB, Kim JS.Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea. J Korean Med Sci. 29(1):61-68, 2014
2014 Hong J, Kim JH, Lee KH, Ahn HK, Park S, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Jan 16. [Epub ahead of print]
2014 Kim JS, Cheong JW, Shin HJ, Lee JW, Lee JH, Yang DH, Lee WS, Kim H, Park JS, Kim SH, Kim YS, Kwak JY, Chae YS, Park J, Do YR, Min YH. Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.Yonsei Med J. 55(1):9-18, 2014
2014 Kim YS, Sym SJ, Park SH, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Lee JH, Shin DB. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.Cancer Chemother Pharmacol. 73(1):163-169. 2014
2014 Kim JS, Cheong JW, Kim YK, Park J, Mun YC, Kang HJ, Yi HG, Lee JH, Kim YS, Ryoo HM, Kim SH, Kim HY, Kim JY, Lee DG, Kim HG, Kim H, Joo YD, Min YH. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea.Ann Hematol. 93(1):33-42.2014
2013 Choi H, Jung C, Sohn SK, Kim S, Kim HJ, Kim YK, Kim T, Zhang Z, Shin ES, Lee JE, Moon JH, Kim SH, Kim KH, Mun YC, Kim H, Park J, Kim J, Kim D. Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype.Br J Haematol. 163(1):62-71. 2013
2013 Park MJ, Park SH, Park PW, Seo YH, Kim KH, Jeong JH, Kim MJ, Ahn JY, Lee JH, Park J, Hong J. Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia.Int J Hematol. 98(5):549-557. 2013
2013 Hong J, Yoon HH, Ahn HK, Sym SJ, Park J, Park PW, Ahn JY, Park S, Cho EK, Shin DB, Lee JH. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma.Acta Haematol. 2130(4):305-311.2013
2013 Jeong JH, Park SH, Park MJ, Kim MJ, Kim KH, Park PW, Seo YH, Lee JH, Park J, Hong J, Ahn JY. N-ras mutation detection by pyrosequencing in adult patients with acute myeloid leukemia at a single institution.Ann Lab Med. 33(3):159-166.2013
2013 Hong J, Moon SM, Ahn HK, Sym SJ, Park YS, Park J, Cho YK, Cho EK, Shin DB, Lee JH. Comparison of characteristics of bacterial bloodstream infection between adult patients with allogeneic and autologous hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 19(6):994-999.2013
2013 Lee YG, Kim I, Yoon SS, Park S, Cheong JW, Min YH, Lee JO, Bang SM, Yi HG, Kim CS, Park Y, Kim BS, Mun YC, Seong CM, Park J, Lee JH, Kim SY, Lee HG, Kim YK, Kim HJ; Korean Society of Haematology AML/MDS working party. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.Br J Haematol. 161(3):339-347. 2013
2013 Sym SJ, Hong J, Park J, Cho EK, Lee JH, Park YH, Lee WK, Chung M, Kim HS, Park SH, Shin DB. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.Cancer Chemother Pharmacol. 71(2):481-488. 2013
2013 Hong J, Kim JY, Ahn HK, Lee SM, Sym SJ, Park J, Cho EK, Ahn JY, Park S, Lee SP, Shin DB, Lee JH. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.Support Care Cancer. 21(4):1145-1152. 2013
2013 Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim H, Park J, Min WS, Kim HJ, Kim DH; L/MDS working party, Korean Society of Hematology. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement .Ann Hematol. 92(2):163-171.2013.
2012 Rim MY, Hong J, Yo I, Park H, Chung DH, Ahn JY, Park S, Park J, Kim YS, Lee JH. Cervical lymphadenopathy mimicking angioimmunoblastic T-cell lymphoma after dapsone-induced hypersensitivity syndrome.Korean J Pathol. 46(6):606-610. 2012
2012 Hong J, Park S, Baek HL, Jung JH, Kang IG, Sym SJ, Park J, Ahn JY, Cho EK, Kim ST, Shin DB, Lee JH. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type.Int J Clin Exp Pathol. 5(9):939-947. 2012
2012 Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Lee SI, Kang HJ, Choi CW, Park J, Song MK, Kim HJ, Kwon JH, Kwak JY, Bae SH, Park BB, Do YR, Lee HS, Jeong SH, Suh C, Kim HJ. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).Int J Hematol. 96(5):631-637. 2012
2012 Huh J, Kim HJ, Jung CW, Kim HJ, Kim SH, Kim YK, Kim HJ,Shin MG, Moon JH, Sohn SK, Kim SH, Lee WS, Won JH, Moon YC, Kim H, Park J, Min WS, Kim DH. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. Am J Hematol. 87(10):961-968 , 2012
2012 Hong J, Park S, Park J*, Jang SJ, Ahn HK, Sym SJ, Cho EK, Shin DB, Lee JH. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. Ann Hematol. 91(12): 1879-1906, 2012
2012 Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung Min, Kim HS, , Lee JH, Shin DB. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 70(2):277-284, 2012
2012 Kim JE, Yoon DH, Jang G, Lee DH, Kim S, Park CS, Huh J, Kim WS, Park J, Lee JH, Lee SI, Suh C. A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas korean J Hematol 47(1) 53-59, 2012-04-18
2012 Hong J, Jung M, Kim YJ, Sym SJ, Kyung SY, Park J, Lee SP, Park JW, Cho EK, Jeong SH, Shin DB, Lee JH. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol. 69 (1) 215-220, 2012
2012 Hong J, Lee Y, Park Y, Kim SG, Hwang KH, Park SH, Jeong J, Kim KH, Ahn JY, Park S, Park J, Lee JH. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol. 91(5) 687-695,2012.
2012 Kang HJ, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS, Lee SR, Lee GW, Kim HJ, Kim HY, Oh SY, Kim HC, Eom HS, Chung J, Park J, Suh C, Ryoo BY. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 91(4):543-551.2012.
2011 Yi JH, Huh Jw, Kim H-J, Kim S-H, Kim H-J, Kim Y-K, Sohn S K, Moon JH, Kim SH, Kim KH, Won JH, Moon YC, Kim H, Park J, Jung CW, Kim DH(Dennis). Adverse prognostic impact of abnormal lesions detected by genome-wide single-nucleotide polymorphism-array based karyotyping analysis in acute myeloid leukemia with normal karyotype. JCO 29(35): 4702-4708, 2011
2011 Noh EM, Cho DH, Lee YR, Jeong YJ, Kim JH, Chae HS, Park J, Jung WS, Park SJ, Kim JS. Dimethylsulfoxide (DMSO) induces downregulation of heme oxygenase-1 (HO-1) in HL-60 cells: involvement of HO-1 in HL-60 cell differentiation. BMB Rep. 44(11):753-757,2011
2011 Hong J, Park S, Park J*, Kim HS, Kim KH, Ahn JY, Rim MY, Jung M, Sym SJ, Cho EK, Shin DB, Lee JH. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk Lymphoma. 52(10):1904-1912, 2011
2011 Lee JH, Jang JH, Park J, Park S, Joo YD, Kim YK, Kim HG, Choi CW, Kim SH, Park SK, Park E, Min YH. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica. 96(10):1441-1447, 2011
2011 Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma. 52(6):1024-1029, 2011
2011 Lee SP, Park S, Park J, Hong J, Ko YH. Clinicopathologic characteristics of CD99-positive diffuse large B-cell lymphoma. Acta Haematol.;125(3):167-174, 2011
2011 Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 10;117(6):1958-1965, 2011
2011 Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, Shin HJ, Yang DH, Choi CW, Park J, Kim WS, Suh C. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. Ann Hematol. 90(5):539-546, 2011
2011 Kim YS, Park SH, Kyung SY, Sym SJ, Lee SP, Park JW, Jung SH, Park J, Cho EK, Lee JH, Shin DB. Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer. Med Oncol. 28(1):342-350. 2011
2010 Kim AD, Kang KA, Zhang R, Lim CM, Kim HS, Kim DH, Jeon YJ, Lee CH, Park J, Chang WY, Hyun JW. Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through the modulation of AMP-activated protein kinase. Environ Toxicol Pharmacol. Sep;30(2):134-140, 2010
2010 Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ. Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. Int J Hematol. 510-517, 2010
2010 Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Sci. 101(11):2443-2447, 2010
2010 Hong J, Kim AJ, Park JS, Lee SH, Lee KC, Park J*, Sym SJ, Cho EK, Shin DB, Lee JH. Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. Korean J Hematol. 45(4):253-259,2010
2010 Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH, And The Korean Multiple Myeloma Working Party (Kmmwp). Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safty. Ann Hematol. 89(9) 905-912, 2010.
2010 Yi HS, Sym SJ, Park J&#8727;,Cho EK, Shin DB, Lee JH. Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia. Leuk Res. 34(7) e173-5, 2010
2010 Oh SY, Kim WS, Kim JS, Kim SJ, , Kwon HC, Lee DH, Won J H , Hwang IG , Kim M K , Lee SI , Chae YS, Yang D-H , Lee G-W , Choi CW , Park J , Suh C , Kim H-J. Pulmonary marginal zone B-cell lymphoma of MALTtype&#8212;What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study. Ann Hematol. 89(6):563-568, 2010.
2010 Hong J, Kyung SY, Lee SP, Park JW, Jung SH, Lee JI, Park SH, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. Korean J Intern Med 25(3):294-300, 2010.
2010 Yi HS, Sym SJ, Park J, Cho EK, Ha SY, Shin DB, Lee JH. Recurrent and metastatic trichilemmal carcinoma of the skin over the thigh: a case report. Cancer Res Treat. 42(3):176-9, 2010
2010 Kim YS, Hong J, Sym SJ, Park SH, Park J, Cho EK, Lee JH, Shin DB. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res Treat. 42(1):24-29. 2010
2010 Park YM, Kim MK, , Won IS, Kim Y, Kyung SY,&#8226;Lee SP, LeeJI, Park JW, Jeong SH, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Clinical characteristics of lung cancer diagnosed from 2006 to 2008: Data from Gachon University Gil Hospital. Korean J Med 78:215-221, 2010
2009 Park YM, Park J*, Jo Y, Kim S-H, Shin K-C, Won IS, Sym SJ, Cho EK, Shin DB, Lee JH. Prolonged Extreme Thrombocytosis in a Postsplenectomy Patient with Hereditary Spherocytosis. Korean J Hematol 44 (4) 298-303, 2009
2009 Park YM, Park J*, Jo Y, Kim S-H, Shin K-C, Won IS, Sym SJ, Cho EK, Shin DB, Lee JH. Prolonged Extreme Thrombocytosis in a Postsplenectomy Patient with Hereditary Spherocytosis. Korean J Hematol 44 (4) 298-303, 2009
2009 Chung WK, Lee BK, Lee Y-R, Park J, Kwon HC. Diallyl Disulfide (DADS) Induces Upregulation of PTEN in Human Leukemia Cells. J Fd Hyg Safety 24 ( 1): 38~45, 2009
2009 Park S-H, Seo Y-H, , Park P-H, Ahn J-Y, Song Y-H, Kim J-E, Park J, Kim K-H. A Case of Primary Autoimmune Myelofibrosis. Korean J Hematol 44:157-162, 2009
2009 Oh SY, Kim WS, Kim JS, Kim SJ, , Kim SH, Lee DH, Won J H , Hwang IG , Kim M K , Lee SI , Kim JG, Yang D-H , Kang HJ, Choi CW , Park J, Choi YJ,Kim HJ, Kwon JH, Suh C , Kim H-J. Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases. Am. J. Hematol. 84:826&#8211;829, 2009.
2009 Park SH, Ha SY, Lee JI, Lee H, Sim H, Kim YS, Hong J, Park J, Cho EK, Shin DB, Lee JH. Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung. J Korean Med Sci; 24: 448-52, 2009
2008 Park SH, Cho EK, Kim Y, Kyung SY, An CH ,Lee SP, Park JW, Jeong SH, Lee JI,&#8226; Choi SJ, Park J, Shin DB, Lee JH. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer Chemother Pharmacol 62:1009&#8211;1014, 2008
2008 Bang S-M, Ahn JY,Park J, Park SH, Park J, Cho EK, Shin DB, Lee JH A. Yoo SJ, Jeon IS,Kim Y-K, Kim H J,Kim H-N, Lee I-K,Kang HJ, Shin HY, Ahn HS Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia. J Korean Med Sci 23: 833-837, 2008
2008 Park SH, Hong J, Kim YS, Kim Y, Kyung SY,&#8226; An CH ,Lee SP, Park JW, Jeong SH, Park J, Cho EK, Shin DB, Lee JH. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer. Lung Cancer 62;72&#8212;77, 2008
2008 Yu HN, Lee YR, Noh EM, Lee KS, Song EK, Han MK, Lee YC, Yim C-Y, Park J, Kim BS, Lee SH, Lee SJ, Kim JS. Tumor necrosis factor-alpha enhances DMSO-induced differentiation of HL-60 cells through the activation of ERK/MAPK pathway. Int J Hematol 87:189&#8211;194, 2008
2008 Park SH, Kim YS, Hong J, Park J, Nam E, Cho EK, Shin DB, Lee JH, Lee WK, Chung M. Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study Anticancer Drugs 9(3):303-7, 2008
2008 Park SH, Cho MS, Kim YS, Hong J, Nam E, Park J, Cho EK, Shin DB, Lee JH, Lee WK.Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. Qual Life Res 17(2):207-214, 2008
2008 Park SH, Nam E, , Park J, Cho EK, Shin DB, Lee JH, Lee WK, Chung M,Lee SI. A. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann Oncol. 19(4):729-733, 2008
2008 Lee KC, Lee SH, Lee Y, Park SH, Park J, Cho EK, Shin DB, Lee JH, Kim DY, Kim ST. Prospective Pilot Study of Consolidation Chemotherapy with Docetaxel and Cisplatin After Concurrent Chemoradiotherapy for Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 71(1):187-191, 2008
2007 Oh SY, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, AhnYC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo B-Y, Lee S-S, Kim HY, Park K, Kim H-J. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. Cancer Letters 258 90&#8211;97, 2007
2007 Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 82(6):446-452, 2007
2007 Lee YR, Yu HN, Noh EM, Kim JS, Song EK, Han MK, Kim BS, Lee SH, Park J*. Peroxisome proliferator-activated receptor γ (PPARγ) and retinoid acid receptor (RAR) synergistically upregulate the tumor suppressor PTEN in human promyeloid leukemia cells. Int J Hematol 85:231-237, 2007
2006 Lee J, Suh C, Park YH, Ko YH., Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim J H, Park J, Oh SJ, Kim K, Jung CW, Park K, and Kim WS. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006
2006 Park J, Kang KA, Zhang R, Piao MJ, Park S. Kim JS, Kang SS and Hyun JW. Antioxidant and cytotoxicity effects of luteolin. Journal of Toxicology and Public Health 22 (4): 391-395, 2006
2006 Park J, Kang KA, Zhang R, Piao MJ, Park S. Park JS, Kim YK, Rho MC, Lee HS and Hyun JW Antioxidant activity of water extract from the cultured mycelia of Phellinus baumii. Cancer Prevention Research 11(4): 325-335, 2006
2006 Kang KA, Zhang R, Piao MJ, Park S, Park J, Kim JS, Kang SS and Hyun JW. Screening of Antioxidant and anticancer effect from flavonoids. Cancer Prevention Research 11(3): 227-235, 2006
2005 Lee YR, Park J, Yu HN , Kim JS , Youn HJ, Jung S. Up-regulation of PI3K/Akt signaling by 17 β -estradiol throughactivation of estrogen receptor-α, but not estrogen receptor-β, and stimulates cell growth in breast cancer cell Biochem. Biophys. Res. Commun. 336(4): 1221-1226, 2005
2005 Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K.Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 13(5): 859-864, 2005
2005 Lee YR, Shim HJ, Yu HN, Song EK, Park J, Kwon KB, Park JW, Rho HW, Park BH, Han MK, Kim JS. Dimethylsulfoxide induces upregulation of tumor suppressor protein PTEN through nuclear factor-kappaB activation in HL-60 cells. Leuk Res 29(4): 401-405, 2005
2005 Lee J, Lee MH , Park KW, Kang JH, Im DH, Kim K, Lee S-H, Kim WS, Park J, Jung CW, Park K. Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. Int J Hematol 81(3):258-263, 2005
2004 Kim HY, Lee MH, Kim JH, Lee SH, Park J, Kim K, Park QE, Kim WS, Jung CW and Park K. Significance of multidrug resistance (MDR) activity in remission induction & survival of acute myeloid leukemia. Kor J Hematol 39(4):209-216, 2004
2004 Park SH, Kang WK, Lee HR, Park J, Lee K-E, Lee S-H, Park JO, Kim K, Kim WS, Chung CW, Im Y-H, Lee MH, Park CH, Park K. Docetaxel plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil based Regimen. Am J Clin Oncol 27(5):477-480, 2004
2004 Kim JH,Lee SH, Park J, Kim HY, Lee SI, Nam EM, Park JO, Kim K, Jung CW, Park YS, Im Y-H, Kang WK, Lee MH, and Park K. Extra-pulmonary Small-Cell Carcinoma: A single-institution experience. Jpn J Clin Oncol 34(5):250-254,2004
2004 Lee SH, Lee J, Park J, Park SH, Lee KE, Lee SI, Nam E, Park JO, Kim K, Jung CW, Park YS, Yoon SS, Kang WK, Lee MH, Park K, Im YH. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 21(3): 223-231,2004
2004 Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim JH, Kim HY, Park SH,, Lee K-E, Park JO, Kim K, Jung CW, Park YS, Im Y-H, Kang WK, Lee MH, and Park K. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer. Clin Cancer Res 10: 4383-4388, 2004
2004 Lee SH, Kang WK, Park J, Kim JH, Kim HY, Lee SI, Kim HYLee SI, Park JO, Kim K Jung CW, Park YS, Im Y-H, Lee MH and Park K. Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br J Cancer 91(1):18-22, 2004
2004 Kim JH, Lee SH, Park J, Kim HY, Lee SI, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K, Han JH, Ko YH. Primary Pulmonary Non-Hodgkin's Lymphoma. Jpn J Clin Oncol 34(9):510-514, 2004
2004 Lee J , Lee MH, Kim WS, Kim K, Park SH, Lee S-H, Lee K-E, Park J, Park JO, Chung CW, Im Y-H, Kang WK, Park K. Tuberculosis in hematopoietic stem cell transplantat recipients in korea. Int J Hematol 79(2):185-188, 2004
2004 Park SH, Lee MH, Lee SH, Lee KE, Park J, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K, Kim SW, Lee KH, Lee JH. The outcomes of hypertransfusion in major ABO Incompatible allogeneic stem cell transplantation. J Korean Med Sci. 19(1):79-82, 2004
2004 Lee S-H, Ahn YC, Kim HJ, Lim DH, Lee SI, Nam EM, Park SH, Park J, Lee K-E, Park JO, Kim K, Kim WS, Jung CW, Im Y-H, Kang WK, Lee MH, Park K. Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer. Jpn J Clin Oncol 33(12): 620-625, 2004
2003 Park J, Lee MH, Lee HR, Park SH, Lee SH, Lee K-E, Lee H, Park JO, Kim K, Jung CW, Im Y-H, Kang WK, Ko Y-H, and Park K. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia . Bone Marrow Transplant 32: 889-895,2003
2003 Park J, Ahn YC, Kim H, Lee S-H, Park SH, Lee K-E, Lim DH, Park JO, Kim K,Jung CW, Im Y-H, Kang WK, Lee MH, Park K: A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer 42: 227-235, 2003
2003 Park J, Suh C, Yang J, Park JS, Park KU, Min YJ, Kim HJ, Kim Y-H, Kim S-H. Active Immunization Using Dendritic Cells Mixed With Tumor Cells Inhibits The Growth Of Lymphomas. J Korean Med Sci 18: 372-380, 2003
2001 Park KU, Kim SH, Suh C, Kim S, Lee SJ, Park JS, Cho HJ, Kim KW, Lee K, Kim HJ, Park J, Min YJ, Kim TW, Lee JW, Kim SB, Kim SW, Lee KH,Lee JS. Correlation of Hematopoietic progenitor cell count determined by the SE-9000TM automated hematology analyzer with CD34+ cell count by flow cytometry in leukapheresis products. Ame J Hematol 67:42-47,2001
2001 Kim DY, Ko YJ, Park J . Hyperadhesiveness of pulmonary endothelial cells toward neutrophils by Vibrio vulnificus cytolysin. Chonbuk Univ Med J 25(2):21-32, 2001
2000 Kim HJ, Suh C, Kim SH, Kim SW , Kim SB, Kim KW, Cho HJ, Min YJ, Park J, Kim Ahm, Lee IS, Lee PR, Chi HS , Seo JJ, Kang W
More